

The ISGIDAR NEWSLETTER

VOL. 22, NO. 1
March, 1996

INTERNATIONAL STUDY GROUP INVESTIGATING DRUGS AS REINFORCERS

CORRESPONDENCE

ABOUT ISGIDAR:
(*President of ISGIDAR*)

R. J. Lamb
DART (MS 984)
Department of Psychiatry
Medical College of Pennsylvania and
Hahnemann University
Broad & Vine Streets
Philadelphia, PA 19102-1192
tel: (215) 762-8387
email: LAMBR@HAL.HAHNEMANN.EDU

ABOUT ISGIDAR NEWSLETTER:
(*Secretary of ISGIDAR*)

Patrick M. Beardsley, Ph.D.
Medical College of Virginia
Department of Pharmacology & Toxicology
P. O. Box 980613
410 N. 12th St., Smith Bld. #756A
Richmond, VA 23298-0613
tel: (804) 828-5185
email: PBEARDSLEY@GEMS.VCU.EDU

1996 ISGIDAR SCIENTIFIC MEETING -- SAN JUAN, PUERTO RICO

The 1996 annual ISGIDAR meeting will be held Saturday 22 June 1996 at the Caribe Hilton in San Juan, Puerto Rico. As usual, the meeting will be held as a satellite session immediately preceding the annual scientific meeting of the Committee on Problems of Drug Dependence. ISGIDAR registration will begin at 8:00 am. The registration fee is \$25. Paper presentations will be scheduled between 9 am and 5 pm, and the business meeting will be held from 5 to 5:30 pm.

To present a paper at the ISGIDAR meeting, please send an abstract by May 1, 1995 to Rick Lamb at the address listed above. Abstracts should conform to the format used for presentations at CPDD. Please note that papers submitted to ISGIDAR should not also be presented at CPDD. The amount of time available for each talk will depend on the number of papers submitted but will not be less than 20 minutes.

I have arranged with Chris Ellyn Johanson, the Editor of Drug and Alcohol Dependence, to have the abstracts of the talks presented at ISGIDAR published in Drug and Alcohol Dependence. This is the reason for requiring abstracts to conform to the CPDD format this year. Final versions of the abstracts as you wish for them to be published should be turned in at the meeting in June.

1996 ISGIDAR Lunch

We are again arranging to have lunch catered by the hotel, so that we can eat together and continue discussions from the morning session. The lunch will cost \$15 per person. Because in past years we have had difficulty estimating the number of people wanting lunch, which has

resulted in some cases in large drains in the ISGIDAR treasury and in other cases in pleading and begging with hotel staff, we are asking that those wishing to join us for the ISGIDAR lunch send in their lunch payments in advance. These should be sent to Marilyn Carroll at the address below. If you wish, you may also advance register (\$25) at the same time. Receipts for meal costs (and registration) will be provided at the meeting. Please, let the various members of your lab who will be attending ISGIDAR, but might not receive the Newsletter, know about lunch. While there will be a limited number of seats available for those failing to send in advance payments, these will be strictly limited and will be available on a first come first serve basis.

Submit lunch payments to

Dr. Marilyn Carroll
Psychiatry Department
Box 392 UMHC
University of Minnesota
Minneapolis, MN 55455

PLEASE MAKE CHECKS PAYABLE TO ISGIDAR
DEADLINE FOR SUBMISSION: May 1, 1995

DIRECTOR OF NIDA TO SPEAK AT THE ISGIDAR ANNUAL MEETING

Dr. Alan Leshner, Director of the National Institute on Drug Abuse, has accepted an invitation by ISGIDAR to speak at its annual meeting. The Secretary of ISGIDAR asked Dr. Leshner if he would discuss with our membership his vision of what he sees would be important contributions from behavioral technology to our understanding of, and fight against, the problems of drug abuse and he has graciously consented to do. It was communicated to Dr. Leshner that many of our membership have been trained within both the pharmacological and psychological sciences and he would be addressing scientists most properly trained to develop new behavioral technologies to benefit our understanding of drug abuse disorders. It will likely be an interesting and provocative presentation and all ISGIDAR members are greatly encouraged to attend. To my knowledge this will be the first time that an acting Director of NIDA has officially addressed our organization.

NOMINATIONS FOR INVITED SPEAKERS

Everyone is encouraged to submit names of people that they would like to see invited to speak at ISGIDAR. Candidates should be individuals doing work relevant to the study of the reinforcing effects of drugs, but who do not usually attend the annual ISGIDAR scientific meeting. Please send names to Rick Lamb at the address on the first page.

1996 TRAVEL AWARD: STUDENT PAPER COMPETITION

Student Travel Award

ISGIDAR will again sponsor a Student Paper Competition Award for a new investigator to present a paper on drug self-administration research. Up to \$500 in reasonable and documented travel costs will be paid to the winner to present a paper at ISGIDAR. Payment will be made upon submission of travel receipts to the ISGIDAR Treasurer. Those who do not receive the

award, but who receive good reviews will be encouraged to present their papers at the ISGIDAR meeting.

ELIGIBILITY: Applicants must be enrolled in a graduate program and be working toward a doctorate or have received their doctorate within the last five years (after June 1, 1991).

Applicants who are not ISGIDAR members must be sponsored by an ISGIDAR member.

The research to be reported at ISGIDAR must not already be published.

MANUSCRIPT REQUIREMENTS: Papers should not be more than 10 pages excluding figures and references.

The length and scope of the paper should be consistent with a 20-25 minute slide presentation.

Please include paper title, name, address, phone number and author's signature on the cover page of the manuscript. The signature and typed name of the author's sponsor should also appear on the cover page after a statement indicating that the applicant made a significant scientific contribution to the research. Submit four copies, double-spaced.

REVIEW: Each manuscript will be independently reviewed by the ISGIDAR officers for originality, scientific contribution, methodology and clarity. Blind review is possible upon request. Reviewers will not participate in the review of papers from their own institution.

Submit manuscripts to

R. J. Lamb
DART (MS 984)
Department of Psychiatry
Medical College of Pennsylvania and
Hahnemann University
Broad & Vine Streets
Philadelphia, PA 19102

DEADLINE FOR SUBMISSION: May 1, 1994

POST-DOCTORAL POSITIONS AND FELLOWSHIPS

POST-DOCTORAL POSITIONS

Postdoctoral positions are anticipated in nicotine/smoking research with Dr. Ken Perkins or Dr. Saul Shiffman at the University of Pittsburgh.

Dr. Shiffman's work focuses on processes that promote smoking relapse, including nicotine dependence, craving, mood disturbance, and coping. There is also opportunity to become involved in a variety of projects that apply field data collection using computer diaries to a range of behavioral medicine areas.

Dr. Perkins' research emphasizes human behavioral pharmacology involving nicotine and smoking. Projects include the relationship of nicotine discrimination and tolerance to tobacco dependence and self-administration. Involvement in clinical research examining the role of weight gain on success of smoking cessation is also possible.

Interested candidates should send a C.V. to Drs. Perkins or Shiffman at the addresses below.

Ken Perkins, Ph.D.
 Western Psychiatric Institute
 University of Pittsburgh School of Medicine
 3811 O'Hara Street
 Pittsburgh, PA 15213

Saul Shiffman, Ph.D.
 Department of Psychology
 University of Pittsburgh
 130 N. Bellefield Avenue, Suite 510
 Pittsburgh, PA 15261

POSTDOCTORAL RESEARCH FELLOWSHIP IN SUBSTANCE ABUSE:

Three research fellowships positions (2-3yrs) are available in a stimulating and productive laboratory and clinic. *The first position* - responsibilities will be to participate in studies on the behavioral and pharmacological treatment of opioid and heroin dependence. Includes research on new pharmacotherapy, buprenorphine, as well as behavioral treatment. **For this position contact: Warren K. Bickel, Ph.D.** *The second position* - is to conduct laboratory self-administration studies in humans and/or treatment studies of smoking cessation. **For this position contact: John R. Hughes, M.D.** *The third position* entails participating in the development, conduct, and publication of studies on behavioral treatments for cocaine dependence. Participation in conducting laboratory studies examining factors influencing human cocaine self-administration is also possible. **For this position contact: Stephen T. Higgins, Ph.D.** For all positions, applicants must have completed doctoral training in psychology or pharmacology and have research experience. Individuals from disadvantaged groups are encouraged to apply. Competitive stipends. Send letter of interest, vita, and letters of reference to the individual named above at: The University of Vermont, Dept. of Psychiatry, Human Behavioral Pharmacology Laboratory, 38 Fletcher Place, Burlington, VT 05401-1419.

BIBLIOGRAPHY

This is a listing of recent publications on drug reinforcement or on the behavioral pharmacology of drugs of abuse submitted by ISGIDAR members: RA=reprint available; IP=in press; NA=reprint not available.

Jonathan L. Katz, Ph.D.
Psychobiology Section
NIDA Addiction Research Center
P.O. Box 5180
Baltimore, MD 21224

- Woods, J.H., Katz, J.L. and Winger, G. Abuse and therapeutic use of benzodiazepines and benzodiazepine-like drugs. In F. E. Bloom and D. J. Kupfer (Eds.). *Psychopharmacology: The Fourth Generation of Progress*. New York: Raven Press, Ltd., 1995, pp. 1777-1791. (RA)
- Acri, J.B., Carter, S.R., Alling, K., Geter-Douglass, B., Dijkstra, D., Wikstrm, H., Katz, J.L. and Witkin, J.M. Assessment of cocaine-like discriminative stimulus effects of dopamine D3 receptor ligands. *European Journal of Pharmacology*, 281: R7-R9, 1995. (RA)
- Newman, A.H., Kline, R.H., Allen, A.C., Izenwasser, S., George, C. and Katz, J.L. Novel 4'- and 4',4"-substituted-3-(diphenylmethoxy)tropane analogs are potent and selective dopamine uptake inhibitors. *Journal of Medicinal Chemistry*. 38: 3933-3940, 1995. (RA)
- Izenwasser, S., Newman, A.H., Cox, B.M. and Katz, J.L. The cocaine-like behavioral effects of meperidine are mediated by activity at the dopamine transporter. *European Journal of Pharmacology*, 297: 9-17, 1996. (RA)
- Kline, R.H., Izenwasser, S., Katz, J.L. and Newman, A.H., 3'-Chloro-3-(diphenylmethoxy)tropane but not 4'-chloro-3-(diphenylmethoxy)tropane produces a cocaine like behavioral profile. *Journal of Medicinal Chemistry*. 00: 0000-0000. (IP)

Aronson, B., Enmon, J.L., Izenwasser, S., Katz, J.L., Kelkar, S.V., Luo, L., Nolan, S.P. and Trudell, M.L. Synthesis and ligand binding of 6-(2-carbomethoxy-3-phenyltropane) transition metal complexes. *Journal of Medicinal Chemistry*. 00: 0000-0000. (IP)

William L. Woolverton, Ph.D., Professor and Director
Division of Neurobiology and Behavior Research
Department of Psychiatry and Human Behavior
University of Mississippi Medical Center
2500 N. State Street Jackson, MS 39216
phone: 601-984-58984 FAX: 601-984-5899

Weed, M.R., Mackevicius, A.S., Keabian, J. and Woolverton, W.L.: Reinforcing and discriminative stimulus effects of DF -CIT in rhesus monkeys. *Pharmacol. Biochem. Behav.* 51: 953-956, 1995.

Woolverton, W.L.: Comparison of the reinforcing efficacy of cocaine and procaine in rhesus monkeys responding under a progressive-ratio schedule. *Psychopharmacology* 120: 296-302, 1995.

English, J.A., Rowlett, J.K. and Woolverton, W.L.: Unit price analysis of opioid consumption by monkeys responding under a progressive-ratio for schedule of opioid injection. *J. Exp. Anal. Behav.* 64: 361-371 1995.

Rowlett, J.K. and Woolverton, W.L.: Evaluation of the effects of cocaine, heroin and naltrexone, alone and in combination, on milk drinking in rats. *Behav. Pharmacol.* 6: 821-829, 1995.

Woolverton, W.L. and Nader, M.A.: Effects of several benzodiazepines, alone and in combination with flumazenil, in rhesus monkeys trained to discriminate pentobarbital from saline. *Psychopharmacology* 122: 230-236, 1995.

Weed, M.R. and Woolverton, W.L. The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys. *J. Pharmacol. Exp. Ther.* 275:

Leslie Amass, Ph.D.
Email: lamass@arf.org
Addiction Research Foundation
Toronto, ON M5S 2S1Canada
Phone: (416)595-682333 Russell St.
FAX: (416)595-6619

Amass, L., Bickel, W.K., Crean, J.P., Blake, J. and Higgins, S.T. Alternate-day buprenorphine dosing is equally efficacious and is preferred daily dosing in opioid-dependent humans. (SU).

Kohji TAKADA, Ph.D.
takada@cica.ac.jp

Takada, K.: Drug discrimination studies in humans - a review of methodologies. *Meth. Find. Exp. Clin. Pharmacol.* 18 (Suppl. A): 187-196, 1996 (RA)

Wakasa, Y., Takada, K. and Yanagita, T.: Reinforcing effect as a function of infusion speed in intravenous self-administration of nicotine in rhesus monkeys. *Jpn J. Psychopharmacol.* 15: 53-59, 1995 (RA)

R. A. Meisch, M.D., Ph.D.
U.T. Psychiatry-Houston
1300 Moursund
Houston, TX 77030
tel (713) 894-1440

- Macenski, M.J., and Meisch, R.A. Oral drug reinforcement studies with laboratory animals: Applications and implications for understanding drug-reinforced behavior. *Current Directions in Psychological Science* 3:22-27, 1994. (RA)
- Meisch, R.A. and Stewart, R.B. Ethanol as a reinforcer: A review of laboratory studies with non-human primates. *Behavioural Pharmacology* 5:425-440, 1994. (RA)
- Stewart, R.B., Lemaire, G.A., Roache, J.D., and Meisch, R.A. Establishing benzodiazepines as oral reinforcers: Midazolam and diazepam administration in rhesus monkeys. *Journal of Pharmacology and Experimental Therapeutics* 271:200-211, 1994 (RA)
- Meisch, R.A. Oral self-administration of etonitazene in rhesus monkeys: Use of a fading procedure to establish etonitazene as a reinforcer. *Pharmacology Biochemistry and Behavior* 50:571-580, 1995. (RA)
- Meisch, R.A., & Stewart, R.B. Relative reinforcing effects of different doses of orally delivered cocaine. *Drug and Alcohol Dependence* 37:141-147, 1995 (RA)
- Roache, J.D., Meisch, R.A., Henningfield, J.E., Jaffe, J.H., Klein, S., and Sampson, A. Reinforcing effects of triazolam in sedative abusers: Correlation of drug linking and self-administration measures. *Pharmacology Biochemistry and Behavior* 50:171-179, 1995. (RA)
- Macenski, M.J., & Meisch, R.A. Oral cocaine self-administration in rhesus monkeys: Strategies for engendering reinforcing effects. *Experimental and Clinical Psychopharmacology* 3: 129-139, 1995. (RA)
- Bell, S.M., Silverman, P.B., Lemaire, G.A., & Meisch, R.A. The failure of cocaine to serve as an orally self-administered reinforcer in Lewis rats. *Behavioural Pharmacology* 6: 366-374, 1995. (NA)
- Meisch, R.M., Stewart, R.S. and Wang, N.-S. Orally delivered methadone as a reinforcer for rhesus monkeys. The relation between drug concentration and choice. *Pharmacology Biochemistry and Behavior* 1996, in press. (IP)
- Spiga, R., Grabowski, J., Silverman, P.B. and Meisch, R.A. Human methadone self-administration: Effects of dose and ratio requirement. *Behavioural Pharmacology* 1996, in press. (IP)
- Stewart, R.B., Grabowski, J., Wang, N.-S. and Meisch, R.A. Orally delivered methadone as a reinforcer in rhesus monkeys. *Psychopharmacology* 123:111-118. (RA)
- Stewart, R.B., Bass, A.A., Wang, N.-S., & Meisch, R.A. Ethanol as a reinforcer normal weight rhesus monkeys. Dose-response functions. *Alcohol* 1996, (IP)

CHRISTINE ANNE SANNERUD, Ph.D.
Drug Sciences Specialist
Office of Diversion Control
Drug Enforcement Administration
Washington, D.C. 20537
PH: (202) 307-7192
FAX: (202) 307-8570
e-mail: sannerud@justice.usdoj.gov

- Sannerud, C.A., and Ator, N.A. Drug discrimination analysis of midazolam under a three-lever procedure I: Dose-dependent differences in generalization and antagonism. *Journal of Pharmacology and Experimental Therapeutics*. 272:100-111, 1995. (RA)
- Sannerud, C.A. Kaminski, B.J., and Griffiths, R.R. Maintenance of H1 antagonists self-injection in baboons. *Experimental and Clinical Psychopharmacology*. 3: 26-32, 1995.
- Sannerud, C.A. and Ator, N.A. Drug discrimination analysis of midazolam under a three-lever procedure II: Differential effects of benzodiazepine receptor agonists. *Journal of Pharmacology and Experimental Therapeutics*. 275:183-193, 1995. (RA)

- Acri, J., Serdikoff, S.L., Witkin, J.M., and Sannerud, C.A. Discriminative stimulus effects of the benzodiazepine partial agonist bretazenil in pigeons and rats. *Behavioural Pharmacology*. 7:72-77, 1996. (RA)
- Kaminski, B.J., Sannerud, C.A., and Griffiths, R.R. Intravenous self-injection of psychomotor stimulant/anorectics in baboons. *Experimental and Clinical Psychopharmacology* (in press). (Not available yet)
- Sannerud, C.A. Kaminski, B.J., and Griffiths, R.R. Intravenous self-injection of four novel phenethylamines in baboons. *Behavioural Pharmacology* (submitted). (Not available yet)
- Mumford, G.K., Benowitz, N.L., Evans, S.M., Kaminski, B.J., Preston, K.L., Sannerud, C.A., Silverman, K., and Griffiths, R.R. Absorption of methylxanthines following capsules, cola and chocolate. *European Journal of Clinical Pharmacology*. (submitted). (Not available yet)

Ken Perkins, Ph.D.
Western Psychiatric Institute
University of Pittsburgh School of Medicine
3811 O'Hara Street
Pittsburgh, PA 15213

- Perkins, K. A.: Individual variability in response to nicotine. *Behavior Genetics* **25**: 119-132, 1995.
- Perkins, K. A.: Sex differences in nicotine versus non-nicotine reinforcement as determinants of tobacco smoking. *Exper. Clin. Psychopharmacol.* in press.
- Perkins, K. A., D'Amico, D. and Sanders, M.: Influence of training dose on nicotine discrimination in humans. *Psychopharmacology* in press.
- Perkins, K. A., DiMarco, A. and Grobe, J. E.: Nicotine discrimination in male and female smokers. *Psychopharmacology* **116**: 407-413, 1994.
- Perkins, K. A., Grobe, J. E. and D'Amico, D.: Low-dose nicotine nasal spray use and effects during initial smoking cessation. *Exper. Clin. Psychopharmacol.* in press.
- Perkins, K. A., Grobe, J. E. and Fonte: Chronic and acute tolerance to subjective, behavioral, and cardiovascular effects of nicotine in humans. *J. Pharmacol. Exp. Ther.* **270**: 628-638, 1994.
- Perkins, K. A., Grobe, J. E. and Weiss, D.: Nicotine preference in smokers as a function of smoking abstinence. *Pharmacol. Biochem. Behav.* in press.
- Perkins, K. A., Sexton, J. E. and DiMarco, A.: Subjective and cardiovascular responses to nicotine combined with alcohol in male and female smokers. *Psychopharmacology* **119**: 205-212, 1995.

ISGIDAR BIBLIOGRAPHY SUBMISSIONS

The pressroom of the ISGIDAR Newsletter encourages submission of recent references from its membership. References should be submitted only electronically either by diskette mailed to the address below or via email (a bin hex attachment works fine) to the NET address below. Please send references in a format akin to JPET format. Almost any word processing file format (PC or Mac) is digestible.

Thanks,

The Management

For
ISGIDAR BIBLIOGRAPHY SUBMISSIONS

Transmit references to:

Patrick M. Beardsley
 Medical College of Virginia
 Department of Pharmacology & Toxicology
 P. O. Box 980613
 410 N. 12th St., Smith Bld. #756A
 Richmond, VA 23298-0613
 tel: (804) 828-5185
 email: PBEARDSLEY@GEMS.VCU.EDU

NOMINATIONS FOR ISGIDAR

Everyone is encouraged to submit nominations for ISGIDAR membership to the president at the address on the front of the newsletter. New members are essential to maintaining ISGIDAR as a vigorous organization. A letter of recommendation and vita are needed to be considered.

NEW NOMINATIONS FOR ISGIDAR

Lisa Bauer has been nominated for membership to ISGIDAR by Dr. Harriet de Wit. Members are encouraged to vote either approving or rejecting this nomination by cutting the ballot from the newsletter below and returning the ballot by mail to Rick Lamb at the address provided.

R. J. Lamb
 DART (MS 984)
 Department of Psychiatry
 Medical College of Pennsylvania and
 Hahnemann University
 Broad & Vine Streets
 Philadelphia, PA 19102-1192

Nomination for membership:

Lisa Bauer

_____ I approve her membership

_____ I reject her nomination